Intravesical administration of RC48‐ADC demonstrates promising antitumor efficacy in human bladder cancer cells expressing HER2 in vivo, and it is also well tolerated with no detectable local or systemic toxicities at the therapeutic dose. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.